...the end of this Mobihealthnews article on his recent presentation at “Better Health” in Boston, a McKesson-sponsored meeting series, was not what constitutes disruption, but that it has not really started yet, four years later. This will be much to the surprise of many successful and unsuccessful companies (Misfit Shine, ZocDoc, Zeo, 23andMe) and health plans which have stoutly touted their products and services as The True Disruptors. Sorry, you may be only a part of the Big Shift: decentralization. Decentralization will push out parts of healthcare off the hospital and doctor’s office to clinics, retail sites, the workplace and... Continue Reading
Search Results for 23andme
2014: the year of reckoning for the ‘better mousetraps’
...of every point made above. Comes the dawn and sobering realizations You look back for leading indicators, and the big one in the rear view mirror is the mHealth Summit, probably the single largest gathering of the mHealth/health tech crowd in the world. Lois Drapin’s articles which appeared here [TTA 23 Dec, 10 Dec] were a scherzo in a minor key: the hundreds of millions of VC funds going to relatively few companies that have yet to turn a profit, one of which (23andMe) was stopped dead in its marketing USP by FDA and a class-action lawsuit; investment capital jumping... Continue Reading
23andMe as Rorschach test
[grow_thumb image=”https://telecareaware.com/wp-content/uploads/2013/12/rorschach1.jpg” thumb_width=”125″ /]Just like the good doctor’s ink blot, there’s a lot of ‘reading into’ the travails of genomic ‘spit test’ 23andMe. Blogger PF Anderson, the Emerging Technologies Librarian for the University of Michigan Health Sciences Libraries, has collected them in pithy quotes and citations. For your weekend or holiday exploration: Collecting Thoughts on the FDA vs. 23andMe... Continue Reading
mHealth Summit 2013: Sunday Venture+ Forum
...date (AirStrip or Fitbit for example); some have raised over $100m (23andMe, Practice Fusion); and then there are companies that investors have pumped over $150m into (ZocDoc, Castlight, PatientSafe, Proteus). 2) The fact that many investors are first time investors, jumping in late, and even large investors in health for the first time. 3) The caution signal with the curvy line that tells us the cycle for exiting is 7 to 10 years. Jack’s starting the mathematical climb and just as I am beginning to feel the first signs of Climber’s Regret, he asks: “How many of these companies are... Continue Reading
The inevitable: class action lawsuit against 23andMe
Breaking News (which is No Big Surprise) Updated 6 December: 23andMe continues to sell kits, but will provide only minimal genomic information and has suspended advertising. The Washington Post reports that “In a statement Thursday night, the firm went a step further, announcing that it would only provide ancestry information and raw health data. A spokesperson for the company said that “interpreted results” would not be included.” 23andMe had earlier this week suspended advertising (Cnet/Reuters). Customers who had purchased kits prior to the FDA letter on 22 November will receive full reports. 23andMe statement on website. Matthew Herper in Forbes... Continue Reading
FDA tells 23andMe genomic test to stop marketing (US)
Quantified Selfers and the D3H (Digital Health Hypester Horde) are in a swivet. This past Friday, FDA slammed the door shut on the 23andMe Personal Genome Service (PGS) saliva test. This past summer, the company broadly marketed to US consumers, including a TV campaign [Charles Lowe, TTA 7 Aug]. The FDA cease-and-desist letter cites that 23andMe never provided requested data on their July and September 510(k) filings, which are now ‘considered withdrawn’, and cites that “after these many interactions with 23andMe, we still do not have any assurance that the firm has analytically or clinically validated the PGS for its... Continue Reading
23andMe advertising nationally in the US (sign of the times)
23andMe, the US personal genetics company, launched Portraits of Health, the company’s first (US) television advertising campaign on 5th August. Anyone unaware of the company and its ambitions could do worse than watch the excellent video of Anne Wojcicki’s presentation at a recent RSM innovations summit. Whilst the NHS talks about building a 100,000 person genomic database, and the RCGP sees the most advanced medical development in the life of the average GP by 2022 will be remote delivery of test results, it seems that 23and Me is powering toward’s Anne’s goal of one million genomes sequenced. It’s not a... Continue Reading
First ‘Lucky Thirteen’ StartUp Health/GE program company sold
Breaking News One of the ‘Lucky Thirteen’ companies, Arpeggi, which entered the joint StartUp Health/GE Ventures program back in April [TTA 4 Apr], has been sold to another early-stage company in the genetics analytics, data management and diagnostic space, Gene by Gene. It is the first acquisition of one of the joint program companies and according to StartUp Health spokesperson Nicole Kinsey, “this is a strong sign of how well the program is is working to accelerate and scale digital health startups. This new combined company will be a major competitor to companies like 23andme and will really offer the... Continue Reading
2012 a breakthrough year for health tech investment, no matter who’s counting
We had earlier this month reported on Rock Health’s digital health estimate of $1.4 billion, up 45% vs. 2011 with 20% going towards the five biggest deals of the year [TA 8 Jan]. Now Austin, Texas-based Mercom Capital Group does its own slightly lower count of $1.2 billion in VC investment in what’s termed HIT, but this is 200% higher than their prior year total of $480 million. There’s overlap but difference in their five big companies: Castlight Health (provider comparison), 23andMe (personal genetics), GoHealth (health insurance comparison), Kinnser Software (home health clinical support) and the Practice Fusion EHR. Mercom... Continue Reading
Most Recent Comments